The seed round was co-led by Kindred Capital, NATO Innovation Fund, and Oxford Science Enterprises.
"In today’s AI race, the limitations of existing hardware – nearly all of which is provided by a single company – represent the biggest barrier to better performance, reduced cost, and wider adoption. Fractile’s approach supercharges inference, delivering astonishing improvements in terms of speed and cost. This is more than just a speed-up – changing the performance point for inference allows us to explore completely new ways to use today’s leading AI models to solve the world’s most complex problems. We’re thrilled to have raised our funding from investors with a wealth of experience in the AI and chip industries, continue to grow our world-class team and further our technological development and partnerships."
The initial tranche of the Series A round was led by DB1 Ventures with backing from Dutch Founders Fund and Flow Traders.
"We are delighted to welcome Deutsche Börse as a shareholder and are very excited to work together with them in further enhancing connectivity and digitisation for capital markets"
Helen Ventures led the seed round with participation from international investors to fund European expansion and product development.
"It is our privilege to join the Renewabl team in their impressive growth story. Consuming clean electricity that matches on an hourly or 15-minute basis is fast becoming an imperative for net-zero-aligned companies – with good reason – whereas tracking and procuring this energy is a challenge,"
— Mikael Myllymäki, Vice President and Head of Helen Ventures
Oshen Holdings led the Series A round with backing from DSW Ventures, SFC Capital, and Boundary Capital.
"I would like to thank all our investors for their trust and support. Our success in continuing to raise investment despite the difficult market conditions over the last few years is testament to their belief in the company’s commercial potential and our world-class team. The funds will be used to complete the pre-clinical testing of our first medical device product range and our preparations for entry into the orthopaedic market."
.png)